1. Cell Cycle/DNA Damage
  2. PPAR


PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ causes insulin sensitization and enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.

PPAR Related Products (41):

Cat. No. Product Name Effect Purity
  • HY-16578
    GW9662 Antagonist
    GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM, with ~10 and ~1000-fold functional selectivity in cells against PPARα and PPARδ, respectively.
  • HY-17386
    Rosiglitazone Agonist
    Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, and is a blocker of TRPM2 and TRPM3 channels.
  • HY-50935
    Troglitazone Inhibitor
    Troglitazone is a PPARγ agonist with anti-inflammatory and anti-tumor activity.
  • HY-14649
    Retinoic acid Agonist
    Retinoic acid is a natural agonist of RAR/RXR nuclear receptors. Retinoic acid also bind to PPARβ/δ, with Kd of 17 nM.
  • HY-14601
    Pioglitazone hydrochloride Agonist
    Pioglitazone hydrochloride is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
  • HY-19937
    Saroglitazar Inhibitor
    Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
  • HY-17618
    Pemafibrate Modulator
    Pemafibrateis a novel selective PPARα modulator (SPPARMα) that has antihyperlipidaemic activity.
  • HY-17618A
    Pemafibrate racemate Modulator
    Pemafibrate (racemate) is a novel selective PPARα modulator (SPPARMα).
  • HY-15725
    CDDO-Im Agonist
    CDDO-Im(RTA-403) is a novel synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo; PPARγ agonist.
  • HY-10838
    GW 501516 Agonist
    GW501516(GSK-516; GW1516) is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.
  • HY-16737
    Elafibranor Agonist
    Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.
  • HY-13202
    T0070907 Antagonist
    T0070907 is a potent a PPARγ antagonist and a potential RAD51 inhibitor, with the IC50 of 1 nM towards PPARγ.
  • HY-17356
    Fenofibrate Agonist
    Fenofibrate is a relatively potent inhibitor of CYP2C19 (IC50=0.2 μM) and CYP2B6 (IC50=0.7 μM). Fenofibrate is also a well-known PPARα agonist (EC50=30 μM).
  • HY-16995
    Wy-14643 Agonist
    Wy-14,643 (Pirinixic acid) is a moderate agonist of PPARα and PPARγ with IC50 of 36.5 μM and 53.7 μM, respectively.
  • HY-14792B
    Inolitazone dihydrochloride Agonist
    Inolitazone dihydrochloride a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
  • HY-13928
    GW0742 Agonist
    GW0742 (GW610742) is a potent and highly selective PPARδ agonist. EC50 values are 1nM, 1.1μM and 2 μM for transactivation of human PPARδ, -α, and -γ receptors respectively.
  • HY-14600
    Rosiglitazone maleate Agonist
    Rosiglitazone maleate(BRL-49653C) is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-γ(PPARγ).
  • HY-20019
    L-165041 Agonist
    L-165041 is a cell permeable PPARδ agonist which induces adipocyte differentiation in NIH-PPARδ cells.
  • HY-15721
    FH535 Inhibitor
    FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.
  • HY-B0287
    Clofibrate Agonist
    Clofibrate (Atromid-S), a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.